NasdaqGS - Nasdaq Real Time Price ? USD IDEAYA Biosciences, Inc. (IDYA) Follow Compare 30.24 -0.30 (-0.98%) As of 11:10 AM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of the Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in methylthioadenosine phosphorylase (MTAP)-deletion urothelial and non-small cell lung cancer (NSCLC) patients at the 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place on PR Newswire ? 17 days ago IDYA -0.98% IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 26, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan PR Newswire ? 24 days ago IDYA -0.98% IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans With the data and support from the FDA, IDEAYA Biosciences has laid out how its Phase III trial of darovasertib will look. Clinical Trials Arena ? 27 days ago IDYA -0.98% IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM. PR Newswire ? 28 days ago IDYA -0.98% IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PK PR Newswire ? 29 days ago IDYA -0.98% IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. PR Newswire ? last month IDYA -0.98% IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. PR Newswire ? last month IDYA -0.98% News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat The analysts covering IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) delivered a dose of negativity to shareholders today, by... Simply Wall St. ? 2 months ago IDYA -0.98% IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023) IDEAYA Biosciences ( NASDAQ:IDYA ) First Half 2024 Results Key Financial Results Net loss: US$92.3m (loss widened by... Simply Wall St. ? 2 months ago IDYA -0.98% IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update, and announced financial results for the second quarter ended June 30, 2024. PR Newswire ? 2 months ago IDYA -0.98% IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 2 months ago IDYA -0.98% LQDA Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program BEIJING & SOUTH SAN FRANCISCO, Calif., July 31, 2024--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics. Business Wire ? 2 months ago IDYA -0.98% IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics. PR Newswire ? 2 months ago IDYA -0.98% 2315.HK IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event. PR Newswire ? 2 months ago IDYA -0.98% How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97% The mean of analysts' price targets for IDEAYA Biosciences (IDYA) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Zacks ? 2 months ago IDYA -0.98% Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders will have a reason to smile today, with the analysts making... Simply Wall St. ? 3 months ago IDYA -0.98% IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 8,355,714 shares of its common stock at a public offering price of $35.00 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 285,715 shares of common stock at a public offering price of $34.9999 per pre-funded warrant, before underwriting discounts and commissions. This includes the exercise in full by the underwriters of their option to purchase u PR Newswire ? 3 months ago IDYA -0.98% Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates. Zacks ? 3 months ago QURE IDYA -0.98% HLVX IDEAYA Announces Pricing of Public Offering IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,228,572 shares of common stock and pre-funded warrants to purchase 285,715 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $35.00 per share, before underwriting discounts and commissions, and the pre-funded warrants are being sold at a public offering price of $34.9999 pe PR Newswire ? 3 months ago IDYA -0.98% IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $200.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $30.0 million of shares of its common stock. The offering is subject to market and other conditions, and there can be PR Newswire ? 3 months ago IDYA -0.98% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return IDYA S&P 500 YTD -15.01% +22.23% 1-Year +19.57% +38.01% 3-Year +33.98% +28.52%
